Amelioration of cisplatin nephrotoxicity by genetic or pharmacologic blockade of prostaglandin synthesis

Kidney International

Volumn 79, Issue 1, 2011, Pages 77-88

  Jia, Zhanjun ^a   Wang, Ningning ^a   Aoyagi, Toshinori ^a   Wang, Haiping ^a   Liu, Haiying ^a   Yang, Tianxin ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

cisplatin; cyclooxygenase 2; cytokines; microsomal prostaglandin E synthase 1; nephrotoxicity

Indexed keywords

ARACHIDONIC ACID; CELECOXIB; CISPLATIN; CYCLOOXYGENASE 2; PROSTAGLANDIN; PROSTAGLANDIN E SYNTHASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARACHIDONIC ACID METABOLISM; ARTICLE; CONTROLLED STUDY; DRUG INDUCED DISEASE; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; ISCHEMIA; KIDNEY INJURY; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

EID: 78650298415     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.331     Document Type: Article

References (66)

1. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005; 4: 307-320.
2. Cohen SM, Lippard SJ. Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol 2001; 67: 93-130.
3. Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol 2003; 23: 460-464.
4. Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 2008; 73: 994-1007.
5. Luke DR, Vadiei K, Lopez-Berestein G. Role of vascular congestion in cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant 1992; 7: 1-7.
6. Breyer MD, Breyer RM. G protein-coupled prostanoid receptors and the kidney. Annu Rev Physiol 2001; 63: 579-605.
7. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996; 271: 33157-33160.
8. Murakami M, Kudo I. Prostaglandin E synthase: a novel drug target for inflammation and cancer. Curr Pharm Des 2006; 12: 943-954.
9. Trebino CE, Stock JL, Gibbons CP et al. Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc Natl Acad Sci USA 2003; 100: 9044-9049.
10. Uematsu S, Matsumoto M, Takeda K et al. Lipopolysaccharide-dependent prostaglandin E(2) production is regulated by the glutathione-dependent prostaglandin E(2) synthase gene induced by the Toll-like receptor 4/MyD88/NF-IL6 pathway. J Immunol 2002; 168: 5811-5816.
11. Boulet L, Ouellet M, Bateman KP et al. Deletion of microsomal prostaglandin E2 (PGE2) synthase-1 reduces inducible and basal PGE2 production and alters the gastric prostanoid profile. J Biol Chem 2004; 279: 23229-23237.
12. Murakami M, Nakashima K, Kamei D et al. Cellular prostaglandin E2 production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and -2. J Biol Chem 2003; 278: 37937-37947.
13. Murakami M, Naraba H, Tanioka T et al. Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 2000; 275: 32783-32792.
14. Kamei D, Yamakawa K, Takegoshi Y et al. Reduced pain hypersensitivity and inflammation in mice lacking microsomal prostaglandin e synthase-1. J Biol Chem 2004; 279: 33684-33695.
15. Samuelsson B, Morgenstern R, Jakobsson PJ. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev 2007; 59: 207-224.
16. Ramesh G, Reeves WB. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 2002; 110: 835-842.
17. Jiang M, Wang CY, Huang S et al. Cisplatin-induced apoptosis in p53-deficient renal cells via the intrinsic mitochondrial pathway. Am J Physiol Renal Physiol 2009; 296: F983-F993.
18. Kudo I, Murakami M. Prostaglandin e synthase, a terminal enzyme for prostaglandin E2 biosynthesis. J Biochem Mol Biol 2005; 38: 633-638.
19. Jia Z, Zhang A, Zhang H et al. Deletion of microsomal prostaglandin E synthase-1 increases sensitivity to salt loading and angiotensin II infusion. Circ Res 2006; 99: 1243-1251.
20. Wang M, Zukas AM, Hui Y et al. Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc Natl Acad Sci USA 2006; 103: 14507-14512.
21. Francois H, Facemire C, Kumar A et al. Role of microsomal prostaglandin E synthase 1 in the kidney. J Am Soc Nephrol 2007; 18: 1466-1475.
22. Soodvilai S, Jia Z, Wang MH et al. mPGES-1 deletion impairs diuretic response to acute water loading. Am J Physiol Renal Physiol 2009; 296: F1129-F1135.
23. Jia Z, Guo X, Zhang H et al. Microsomal prostaglandin synthase-1-derived prostaglandin E2 protects against angiotensin II-induced hypertension via inhibition of oxidative stress. Hypertension 2008; 52: 952-959.
24. Fuson AL, Komlosi P, Unlap TM et al. Immunolocalization of a microsomal prostaglandin E synthase in rabbit kidney. Am J Physiol Renal Physiol 2003; 285: F558-F564.
25. Yang T. Microsomal prostaglandin E synthase-1 and blood pressure regulation. Kidney Int 2007; 72: 274-278.
26. Deng J, Kohda Y, Chiao H et al. Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney Int 2001; 60: 2118-2128.
27. Banas B, Luckow B, Moller M et al. Chemokine and chemokine receptor expression in a novel human mesangial cell line. J Am Soc Nephrol 1999; 10: 2314-2322.
28. Dickey DT, Wu YJ, Muldoon LL et al. Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. J Pharmacol Exp Ther 2005; 314: 1052-1058.
29. Matsushima H, Yonemura K, Ohishi K et al. The role of oxygen free radicals in cisplatin-induced acute renal failure in rats. J Lab Clin Med 1998; 131: 518-526.
30. Tsuruya K, Tokumoto M, Ninomiya T et al. Antioxidant ameliorates cisplatin-induced renal tubular cell death through inhibition of death receptor-mediated pathways. Am J Physiol Renal Physiol 2003; 285: F208-F218. (Pubitemid 36871193)
31. Sener G, Satiroglu H, Kabasakal L et al. The protective effect of melatonin on cisplatin nephrotoxicity. Fundam Clin Pharmacol 2000; 14: 553-560.
32. Baldew GS, van den Hamer CJ, Los G et al. Selenium-induced protection against cis-diamminedichloroplatinum(II) nephrotoxicity in mice and rats. Cancer Res 1989; 49: 3020-3023.
33. Naziroglu M, Karaoglu A, Aksoy AO. Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats. Toxicology 2004; 195: 221-230.
34. Jiang M, Wei Q, Pabla N et al. Effects of hydroxyl radical scavenging on cisplatin-induced p53 activation, tubular cell apoptosis and nephrotoxicity. Biochem Pharmacol 2007; 73: 1499-1510.
35. Chirino YI, Sanchez-Gonzalez DJ, Martinez-Martinez CM et al. Protective effects of apocynin against cisplatin-induced oxidative stress and nephrotoxicity. Toxicology 2008; 245: 18-23.
36. Pan H, Mukhopadhyay P, Rajesh M et al. Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death. J Pharmacol Exp Ther 2009; 328: 708-714.
37. Moe KT, Aulia S, Jiang F et al. Differential upregulation of Nox homologues of NADPH oxidase by tumor necrosis factor-alpha in human aortic smooth muscle and embryonic kidney cells. J Cell Mol Med 2006; 10: 231-239.
38. Ramesh G, Reeves WB. p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am J Physiol Renal Physiol 2005; 289: F166-F174.
39. Ramesh G, Reeves WB. Salicylate reduces cisplatin nephrotoxicity by inhibition of tumor necrosis factor-alpha. Kidney Int 2004; 65: 490-499.
40. Zhang B, Ramesh G, Norbury CC et al. Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells. Kidney Int 2007; 72: 37-44.
41. Ascon M, Ascon DB, Liu M et al. Renal ischemia-reperfusion leads to long term infiltration of activated and effector-memory T lymphocytes. Kidney Int 2009; 75: 526-535.
42. Day YJ, Huang L, McDuffie MJ et al. Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. J Clin Invest 2003; 112: 883-891.
43. Singbartl K, Forlow SB, Ley K. Platelet, but not endothelial, P-selectin is critical for neutrophil-mediated acute postischemic renal failure. FASEB J 2001; 15: 2337-2344.
44. Wu X, Guo R, Wang Y et al. The role of ICAM-1 in endotoxin-induced acute renal failure. Am J Physiol Renal Physiol 2007; 293: F1262-F1271.
45. Ramesh G, Zhang B, Uematsu S et al. Endotoxin and cisplatin synergistically induce renal dysfunction and cytokine production in mice. Am J Physiol Renal Physiol 2007; 293: F325-F332. (Pubitemid 47345033)
46. Lieberthal W, Levine JS. Mechanisms of apoptosis and its potential role in renal tubular epithelial cell injury. Am J Physiol 1996; 271: F477-F488. (Pubitemid 26328278)
47. Kruidering M, van de Water B, Zhan Y et al. Cisplatin effects on F-actin and matrix proteins precede renal tubular cell detachment and apoptosis in vitro. Cell Death Differ 1998; 5: 601-614.
48. Lopez R, Roig F, Llinas MT et al. Role of cyclooxygenase-2 in the control of renal haemodynamics and excretory function. Acta Physiol Scand 2003; 177: 429-435.
49. Muhlfeld AS, Floege J. COX-2 inhibitor induced anuric renal failure in a previously healthy young woman. Clin Nephrol 2005; 63: 221-224.
50. Patel NS, Cuzzocrea S, Collino M et al. The role of cycloxygenase-2 in the rodent kidney following ischaemia/reperfusion injury in vivo. Eur J Pharmacol 2007; 562: 148-154.
51. Feitoza CQ, Camara NO, Pinheiro HS et al. Cyclooxygenase 1 and/or 2 blockade ameliorates the renal tissue damage triggered by ischemia and reperfusion injury. Int Immunopharmacol 2005; 5: 79-84.
52. Greene SN, Ramos-Vara JA, Craig BA et al. Effects of cyclooxygenase inhibitor treatment on the renal toxicity of cisplatin in rats. Cancer Chemother Pharmacol 2010; 65: 549-556.
53. Al Suleimani YM, Abdelrahman AM, AlMahruqi AS et al. Interaction of nimesulide, a cyclooxygenase-2 inhibitor, with cisplatin in normotensive and spontaneously hypertensive rats. Food Chem Toxicol 2010; 48: 139-144.
54. Ye W, Zhang H, Hillas E et al. Expression and function of COX isoforms in renal medulla: evidence for regulation of salt sensitivity and blood pressure. Am J Physiol Renal Physiol 2006; 290: F542-F549.
55. Zewde T, Mattson DL. Inhibition of cyclooxygenase-2 in the rat renal medulla leads to sodium-sensitive hypertension. Hypertension 2004; 44: 424-428.
56. Smalley WE, DuBois RN. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol 1997; 39: 1-20.
57. Vane JR, Botting RM. Mechanism of action of antiinflammatory drugs. Int J Tissue React 1998; 20: 3-15.
58. Hull MA, Ko SC, Hawcroft G. Prostaglandin EP receptors: targets for treatment and prevention of colorectal cancer? Mol Cancer Ther 2004; 3: 1031-1039. (Pubitemid 39199598)
59. Oshima H, Oshima M, Inaba K et al. Hyperplastic gastric tumors induced by activated macrophages in COX-2/mPGES-1 transgenic mice. Embo J 2004; 23: 1669-1678.
60. Yoshimatsu K, Altorki NK, Golijanin D et al. Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clin Cancer Res 2001; 7: 2669-2674. (Pubitemid 32911370)
61. Yoshimatsu K, Golijanin D, Paty PB et al. Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin Cancer Res 2001; 7: 3971-3976. (Pubitemid 34044615)
62. Nakanishi M, Montrose DC, Clark P et al. Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. Cancer Res 2008; 68: 3251-3259.
63. Senzaki M, Ishida S, Yada A et al. CS-706, a novel cyclooxygenase-2 selective inhibitor, prolonged the survival of tumor-bearing mice when treated alone or in combination with anti-tumor chemotherapeutic agents. Int J Cancer 2008; 122: 1384-1390.
64. Masferrer JL, Leahy KM, Koki AT et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60: 1306-1311.
65. Liu H, Jia Z, Soodvilai S et al. Nitro-oleic acid protects the mouse kidney from ischemia and reperfusion injury. Am J Physiol Renal Physiol 2008; 295: F942-F949.
66. Wei Q, Dong G, Yang T et al. Activation and involvement of p53 in cisplatin-induced nephrotoxicity. Am J Physiol Renal Physiol 2007; 293: F1282-F1291.